期刊文献+

多学科团队模式下结直肠癌肝转移的转化性治疗(附86例报告) 被引量:8

Multi-disciplinary team and conversion therapy for colorectal cancer with unresectable liver metastases:A report of 86 patients
原文传递
导出
摘要 目的探索适用于初始不可切除的结直肠癌肝转移(colorectal liver metastases,CLMs)病人转化性治疗的多学科团队(MDT)模式,评价转化性治疗的安全性和有效性。方法回顾性分析2008年1月至2011年12月复旦大学附属中山医院经过MDT诊治模式并转化性治疗成功的86例CLMs病人的临床资料,评价MDT诊治模式下转化性治疗的实施及近远期疗效,并分析预测病人预后的因素。结果 86例病人随访41.0(24~68)个月,转移灶复发73例,39例死亡。病人的1、2、3年累积总存活率(OS)分别为90.6%、75.6%、65.1%;中位生存时间为(47.5±3.1)个月。1、2、3年无疾病存活率(DFS)分别为72.1%、48.8%、31.4%,中位DFS时间(22.0±2.9)个月,与99例初始可切除性CLMs的OS和DFS相比差异无统计学意义(P〉0.05)。86例病人围手术期病死率1.5%,手术并发症发生率24.4%且经过积极支持治疗后均痊愈。肿瘤缓解程度与早期肿瘤退缩对转化性治疗病人的预后有预测作用。结论对于不可切除的CLMs,MDT指导下的转化性治疗安全、有效,转化治疗成功病人的中期生存效果与初始可切除性CLMs相似,长期生存效果值得期待。 Objective To analyze safety and effect of the conversion therapy for initially unresectable colorectal liver metastases(CLMs) under the guidance of multi-disciplinary team(MDT).Methods The retrospective analysis was conducted for 86 patients with unresectable CLMs received MDT management and arrived conversion therapy successfully from January 2008 to December 2011 in Zhongshan Hospital of Fudan University. The perioperative and survival outcomes,prognostic factors were evaluated.Results During the mean follow-up of 41 months(24-68months), according to the finding time of liver metastases of 86 patients,recurrence events were 73 patients,and 39 patients died. The 1 year,2 year and 3 year overall survival rate(OS) was 90.6%,75.6% and 65.1% respectively. The median OS time was(47.5±3.1)months. The 1 year,2 year and 3 year disease free survival rate(DFS) was 72.1%,48.8% and 31.4% respectively. The median DFS time was(22.0±2.9)months. The OS and DFS were no significant difference when compared 86 patients with initially unresectable CLMs successfully arrived conversion therapy with 99 patients with initial resectable CLMs(P〉0.05). The perioperative mortality rate was 1.5%,and operative complication rate was 24.4%. Tumor regression grade and early tumor shrink could predict the prognosis of CLM patients received conversion therapy.Conclusion The conversion therapy under the guidance of MDT mode is safe and effective for unresectable CLMs. The mid-term survival rate is similar with initially resectable CLMs,and long-term survival is expected.
出处 《中国实用外科杂志》 CSCD 北大核心 2014年第9期862-865,870,共5页 Chinese Journal of Practical Surgery
关键词 结直肠癌 肝转移 转化性治疗 多学科团队 colorectal cancer liver metastases conversion therapy multi-disciplinary team
  • 相关文献

参考文献16

  • 1Adam R, De Gramont A, Figueras J, et al.The oneosurgery ap- proach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus [ J ]. Oncologist, 2012, 17(10):1225-1239.
  • 2Xu J, Qin X, Wang J, et al.Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer[J].J Cancer Res Clin Oncol,2011,137(9): 1379-1396.
  • 3钟芸诗,朱德祥,韦烨,任黎,梁立,潘向欧,翟升永,樊嘉,叶青海,许剑民,秦新裕.结直肠癌肝转移灶手术指征拓展临床应用评价--中国《结直肠癌肝转移诊断和综合治疗指南(V2010)}应用体会[J].中国实用外科杂志,2013,33(8):676-679. 被引量:33
  • 4Schmoll HJ, Van Cutsem E, Stein A, et al.ESMO Consensus Guidelines for management of patients with colon and rectal can- cer. a personalized approach to clinical decision making[J].Ann Oncol, 2012,23(10) : 2479-2516.
  • 5Zelck L, Bugat R, Cherqui D, et al.Muhimodal therapy with in- travenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in nonresect- able hepatic metastases from colorectal cancer [J].Ann Oncol, 2003,14(10) : 1537-1542.
  • 6王福龙,潘志忠.结直肠癌肝转移转化治疗后手术时机及术式选择[J].中国实用外科杂志,2013,33(8):656-659. 被引量:7
  • 7Suzuki C, Blomqvist L, Sundin A, et al.The initial change in tu- mor size predicts response and survival in patients with metastat- ic colorectal cancer treated with combination chemotherapy [J]. Ann Oncol, 2012,23(4) :948-954.
  • 8Silvestri A, Pin E, Huijbers A, et al.lndividualized therapy for metastatic colorectal cancer [J].J Intern Med, 2013, 274(1): 1-24.
  • 9Edwards MS, Chadda SD, Zhao Z, et al.A systematic review of treatment guidelines for metastatic eoloreetal cancer[J].Colorec- tal Dis, 2012,14(2): 31-47.
  • 10Augestad KM, Lindsetmo RO, Stulberg J, et al.International preoperative rectal cancer management: staging, neoadjuvant treatment, and impact of multidisciplinary teams [J].World J Surg, 2010,34(11) : 2689-2700.

二级参考文献24

  • 1汪建平,宋新明,詹文华,兰平,何晓顺,朱晓锋,吴小剑,王东平,邓艳红.直肠癌肝广泛转移肝移植2例报告[J].中国实用外科杂志,2005,25(7):441-442. 被引量:5
  • 2钟芸诗,许剑民,韦烨,任黎,赖衍翰,樊嘉,周俭,钦伦秀,秦新裕.结直肠癌肝转移的外科手术治疗[J].中华肝胆外科杂志,2007,13(2):104-107. 被引量:12
  • 3Adam R, De Gramont A, Figueras J, et al. The oncosurgery ap- proach to managing liver metastases from colorectal cancer:'A multidisciplinary international consensus [J]. Oncologist, 2012, 17(10)1225-1239.
  • 4Schmo11 HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal can- cer. A personalized approach to clinical decision making [J]. Ann Oncol, 2012,23 (10) : 2479-2516.
  • 5NCCN Clincal Practice Guidelines in Oncology. Colon Cancer. 2013 V-3 [ J/OL ] .www.nccn.org/clinical.asp.
  • 6Stillwell AP, Ho YH, Veitch C, et al. Systematic review of prog- nostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases [J ]. World J Surg, 2011, 35(3): 684-692.
  • 7Lupinacci R, Penna C, Nordlinger B. Hepatectomy for resectable colorectal cancer metastases-indicators of prognosis, definition of resectability, techniques and outcomes [J]. Surg Oncol Clin N Am, 2007,16(3):493-506.
  • 8Kopetz S, Chang GJ, Overman M J, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepat- ic resection and improved chemotherapy[J]. J Clin Oncol, 2009, 27(22): 3677-3683.
  • 9Xu J, Qin X, Wang J, et al. Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer [ J ]. J Cancer Res Clin Oncol, 2011,137(9): 1379-1396.
  • 10Adam R, Hoti E, Bredt LC. Evolution of neoadjuvant therapy for extended hepatic metastases-have we reached our (non-resect- able) limit? [J].J Surg Oncol, 2010,102(8): 922-931.

共引文献40

同被引文献72

  • 1许剑民,钟芸诗,牛伟新,任黎,赖衍翰,王建华,颜志平,程洁敏,秦新裕.术前肝动脉联合区域动脉灌注化疗预防结直肠癌术后肝转移[J].中华医学杂志,2006,86(2):88-92. 被引量:20
  • 2刘展,汪晓东,李立.在结直肠癌领域引入多学科协作管理模式的现状[J].中国普外基础与临床杂志,2007,14(1):114-116. 被引量:36
  • 3孙燕,石远凯.临床肿瘤内科手册[M].第4版.北京:人民卫生出版社.2009:519.
  • 4Jankowski J, Sampliner R, Kerr D, et al. Gastrointestinal Oncolo- gy: A Critical Multidisciplinary Team Approach [ M ]. Malden, MA : Blackwell Publishing,2008:728.
  • 5Department of Health. A policy framework for commissioning canc- er services: a report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales [ R ]. London : Department of Heath, 1995.
  • 6Association of Coloproctology of Great Britain and Ireland. Guide- lines for the Management of Colorectal Cancer [ R ]. London: Association of Coloproctology of Great Britain and Ireland ,2007.
  • 7Tocchi C, McCorkle R, Knobf MT. Muhidisciplinary Specialty Teams: A Self-Management Program for Patients With Advanced Cancer[ J]. J Adv Pract 0ncol,2015,6(5) :408-416.
  • 8Richardson B, Preskitt J, Lichliter W, et al. The effect of multi- disciplinary teams for rectal cancer on delivery of care and patient outcome: has the use of muhidisciplinary teams for rectal cancer affected the utilization of available resources, proportion of patients meeting the standard of care, and does this translate into changes in patient outcome? [J]. Am J Surg, 2016,211 (1):46-52. DOI: 10. 1016/j. amjsurg. 2015.08. 015.
  • 9Lan YT, Lin JK, Jiang JK. Effects of a multidisciplinary team on colorectal cancer treatment [ J ]. Formosan Jounaal of Surgery, 2015,48 ( 5 ) : 145-150. DOI : 10. 1016/j. fjs. 2015.07. 003.
  • 10Patkar V, Acosta D, Davidson T, et al. Cancer muhidisciplinary team meetings : evidence, challenges, and the role of clinical deci- sion support technology [ J]. Int J Breast Cancer, 2011,2011 : 831605. DOI: 10. 4061/2011/831605.

引证文献8

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部